195 related articles for article (PubMed ID: 36753540)
21. Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma.
DeMartino J; Meister MT; Visser LL; Brok M; Groot Koerkamp MJA; Wezenaar AKL; Hiemcke-Jiwa LS; de Souza T; Merks JHM; Rios AC; Holstege FCP; Margaritis T; Drost J
Nat Commun; 2023 May; 14(1):3074. PubMed ID: 37244912
[TBL] [Abstract][Full Text] [Related]
22. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
23. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma.
Patel AG; Chen X; Huang X; Clay MR; Komorova N; Krasin MJ; Pappo A; Tillman H; Orr BA; McEvoy J; Gordon B; Blankenship K; Reilly C; Zhou X; Norrie JL; Karlstrom A; Yu J; Wodarz D; Stewart E; Dyer MA
Dev Cell; 2022 May; 57(10):1226-1240.e8. PubMed ID: 35483358
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.
Dorado García H; Pusch F; Bei Y; von Stebut J; Ibáñez G; Guillan K; Imami K; Gürgen D; Rolff J; Helmsauer K; Meyer-Liesener S; Timme N; Bardinet V; Chamorro González R; MacArthur IC; Chen CY; Schulz J; Wengner AM; Furth C; Lala B; Eggert A; Seifert G; Hundsoerfer P; Kirchner M; Mertins P; Selbach M; Lissat A; Dubois F; Horst D; Schulte JH; Spuler S; You D; Dela Cruz F; Kung AL; Haase K; DiVirgilio M; Scheer M; Ortiz MV; Henssen AG
Nat Commun; 2022 Jul; 13(1):4297. PubMed ID: 35879366
[TBL] [Abstract][Full Text] [Related]
25. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Nishimura R; Takita J; Sato-Otsubo A; Kato M; Koh K; Hanada R; Tanaka Y; Kato K; Maeda D; Fukayama M; Sanada M; Hayashi Y; Ogawa S
Cancer Sci; 2013 Jul; 104(7):856-64. PubMed ID: 23578105
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
27. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of impaired differentiation in rhabdomyosarcoma.
Keller C; Guttridge DC
FEBS J; 2013 Sep; 280(17):4323-34. PubMed ID: 23822136
[TBL] [Abstract][Full Text] [Related]
29. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
30. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
[TBL] [Abstract][Full Text] [Related]
31. Differential regulation of autophagy by STAU1 in alveolar rhabdomyosarcoma and non-transformed skeletal muscle cells.
Almasi S; Crawford Parks TE; Ravel-Chapuis A; MacKenzie A; Côté J; Cowan KN; Jasmin BJ
Cell Oncol (Dordr); 2021 Aug; 44(4):851-870. PubMed ID: 33899158
[TBL] [Abstract][Full Text] [Related]
32. RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas.
Tarnowski M; Schneider G; Amann G; Clark G; Houghton P; Barr FG; Kenner L; Ratajczak MZ; Kucia M
Int J Oncol; 2012 Sep; 41(3):995-1004. PubMed ID: 22752028
[TBL] [Abstract][Full Text] [Related]
33. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
34. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
35. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth.
Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C
Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855
[TBL] [Abstract][Full Text] [Related]
36. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
37. Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness.
Poli E; Barbon V; Lucchetta S; Cattelan M; Santoro L; Zin A; Milano GM; Zanetti I; Bisogno G; Bonvini P
Oncoimmunology; 2022; 11(1):2096349. PubMed ID: 35813575
[TBL] [Abstract][Full Text] [Related]
38. The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity.
Thuault S; Comunale F; Hasna J; Fortier M; Planchon D; Elarouci N; De Reynies A; Bodin S; Blangy A; Gauthier-Rouvière C
Mol Biol Cell; 2016 Sep; 27(17):2653-61. PubMed ID: 27413008
[TBL] [Abstract][Full Text] [Related]
39. MiRNAs as Players in Rhabdomyosarcoma Development.
Gasparini P; Ferrari A; Casanova M; Limido F; Massimino M; Sozzi G; Fortunato O
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752446
[TBL] [Abstract][Full Text] [Related]
40. IL-4 receptor blockade abrogates satellite cell: rhabdomyosarcoma fusion and prevents tumor establishment.
Li G; Kikuchi K; Radka M; Abraham J; Rubin BP; Keller C
Stem Cells; 2013 Nov; 31(11):2304-12. PubMed ID: 23897781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
